{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:27:26Z","timestamp":1789198046065,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009980","name":"Medizinische Universit\u00e4t Innsbruck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.euo.2020.10.010","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T10:08:57Z","timestamp":1606126137000},"page":"745-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?"],"prefix":"10.1016","volume":"4","author":[{"given":"Isabel","family":"Heidegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Surcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.10.010_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2019.00490","article-title":"Targeting the tumor microenvironment in renal cell cancer biology and therapy","volume":"9","author":"Heidegger","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0010","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.3747\/co.27.5121","article-title":"Immune checkpoint inhibitors in genitourinary malignancies","volume":"27","author":"Thana","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.trecan.2020.01.003","article-title":"Immune checkpoint inhibition in prostate cancer","volume":"6","author":"Nicholson","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","article-title":"Revisiting immunotherapy: a focus on prostate cancer","volume":"80","author":"Cha","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The tumor immune contexture of prostate cancer","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2020.10.010_bib0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/14712598.2020.1735345","article-title":"Immunotherapy for castration-resistant prostate cancer: has its time arrived?","volume":"20","author":"Slovin","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.euo.2020.10.010_bib0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","article-title":"PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer","volume":"11","author":"Isaacsson Velho","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.euo.2020.10.010_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2020.10.010_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00283","article-title":"Prospective comprehensive genomic profiling of primary and metastatic prostate tumors","volume":"3","author":"Chung","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0055","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.10.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2019.37.7_suppl.142","article-title":"Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650)","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0070","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","article-title":"Immunotherapy of prostate cancer: facts and hopes","volume":"23","author":"Bilusic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0075","first-page":"e261","article-title":"A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer","volume":"183","author":"Tollefson","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.10.010_bib0080","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3389\/fonc.2020.01381","article-title":"Phase II study of ipilimumab in men with metastatic prostate cancer with an incomplete response to androgen deprivation therapy","volume":"10","author":"Graff","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2020.10.010_bib0090","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms20081831","article-title":"Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and\/or enzalutamide therapy","volume":"20","author":"Pal","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2020.10.010_bib0095","first-page":"v325","volume":"30","author":"Yu","year":"2019","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2020.10.010_bib0100","article-title":"Pembrolizumab plus enzalutamide in abiraterone-pretreated patients with metastatic castration-resistant prostate cancer: updated results from keynote-365 cohort","volume":"203","author":"Yu","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.10.010_bib0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0110","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1200\/JCO.2020.38.15_suppl.5543","article-title":"KEYNOTE-199 cohorts (C) 4 and 5: phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Hoimes","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0115","article-title":"IMbassador250: a phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"80","author":"Sweeney","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0120","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","article-title":"Expression of PD-L1 in hormone-naive and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide","volume":"23","author":"Calagua","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2020.10.010_bib0135","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CHECKMATE 9KD","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2020.38.6_suppl.100","article-title":"KEYNOTE-365 cohort A updated results: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Yu","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-050217-121900","article-title":"New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation","volume":"70","author":"Curran","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.euo.2020.10.010_bib0150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/978-1-4939-3387-7_43","article-title":"Cancer vaccines: a brief overview","volume":"1403","author":"Thomas","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.euo.2020.10.010_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.10.010_bib0160","first-page":"77","article-title":"Therapeutic vaccines for prostate cancer","volume":"12","author":"Cha","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.euo.2020.10.010_bib0165","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-16-1780","article-title":"Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial","volume":"23","author":"Antonarakis","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e17564","article-title":"Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer","volume":"38","author":"Rosser","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2019.12.005","article-title":"The impact of radiation therapy on innate and adaptive tumor immunity","volume":"30","author":"Brandmaier","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0190","first-page":"e4103","article-title":"Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.euo.2020.10.010_bib0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0200","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0205","doi-asserted-by":"crossref","unstructured":"Fizazi K., Drake C.G., Beer T.M., et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.032.","DOI":"10.1016\/j.eururo.2020.07.032"},{"key":"10.1016\/j.euo.2020.10.010_bib0210","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","article-title":"Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer","volume":"7","author":"Dudzinski","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0215","article-title":"Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer","volume":"19","author":"Twardowski","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euo.2020.10.010_bib0220","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.10.010_bib0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nrurol.2015.90","article-title":"Targeting bone metastases in prostate cancer: improving clinical outcome","volume":"12","author":"Body","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1200\/JCO.2020.38.6_suppl.130","article-title":"Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)","volume":"38","author":"Marshall","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0235","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ctrv.2005.09.006","article-title":"The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer","volume":"31","author":"Madhusudan","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2020.10.010_bib0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA repair, genome stability and cancer: a historical perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-017-0480-2","article-title":"PARP inhibitors in prostate cancer","volume":"18","author":"Ramakrishnan Geethakumari","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0250","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.10.010_bib0255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0260","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.10.010_bib0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40425-018-0445-4","article-title":"Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition","volume":"6","author":"Fenerty","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2020.10.010_bib0270","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"7 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2019.37.7_suppl.145","article-title":"Keynote-365 cohort A: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"37","author":"Yu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2020.10.010_bib0280","doi-asserted-by":"crossref","first-page":"TPS3156","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3156","article-title":"A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and\/or homologous recombination repair deficiency (HRD): KEYLYNK-007","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.10.010_bib0285","first-page":"680","article-title":"[PSMA radioligand therapy in patients with advanced prostate cancer]","volume":"59","author":"Bogemann","year":"2020","journal-title":"Urologe A"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120301759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120301759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:22Z","timestamp":1762876042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120301759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2588931120301759"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.10.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}